Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Inhaled Ciclesonide Improves Asthma Control: Presented at ACAAI - (DGDispatch)
    Efficacy of Aqueous Triamcinolone Acetonide in Allergic Rhinitis Not Affected by Gender: Presented at ACAAI - (DGDispatch)
    FDA Approves a C1-Esterase Inhibitor for Abdominal Attacks, Facial Swelling Associated With HAE - (DGNews)
    FDA Approves Bepotastine Besilate Solution for Ocular Itching Associated With Allergies - (DGNews)
    FDA Approves Levocetirizine Dihydrochloride for Paediatric Nasal Allergies - (DGNews)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • Advances in Hereditary Angioedema Treatment: Considerations, Criteria & the New Therapy Options for Treatment & Prevention of HAE Attacks
      Sublingual Immunotherapy (SLIT) for Allergic Rhinitis The Latest Evidence
      Update in Hereditary Angioedema: A Disease in Rapid Evolution

      Webcasts/CME archive

       Recent cases - Allergy Other
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Anaphylaxis Following Intravenous Fluorescein Angiography in a Vitreoretinal Clinic: Report of 4 Cases
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        FDA Approves Clarinex (Desloratadine) Syrup for Relief of Symptoms Associated With Indoor and Outdoor Allergies and Hives in Children

        -- Indoor Allergies and Hives for Children Six Months and Older -- Outdoor Allergies for Children Two Years and Older


        KENILWORTH, NJ -- September 2, 2004 -- Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Clarinex® (desloratadine) Syrup for the relief of symptoms associated with seasonal allergic rhinitis (SAR) (outdoor allergies) in children two years and older and perennial allergic rhinitis (PAR) (indoor allergies) and chronic idiopathic urticaria (CIU), or hives of unknown cause in children as young as six months. The approval of the CIU and PAR indications makes it the only prescription non-sedating antihistamine syrup on the market for a patient population as young as six months. The new Clarinex Syrup is expected to be available in the U.S. during the first half of 2005.


        Clinical Trials
        The FDA approval of the new Clarinex Syrup results from three double- blind, placebo-controlled safety studies involving 246 pediatric subjects six months to 11 years of age with a documented history of allergic rhinitis, chronic idiopathic urticaria, or subjects who were candidates for antihistamine therapy. The results of these studies demonstrated the safety of Clarinex Syrup in pediatric subjects six months to 11 years of age.

        In clinical trials, the overall incidence of adverse events in children six years through 11 years of age was similar for the desloratadine syrup and the placebo groups. In pediatric patients six months to five years of age, the most frequently seen adverse events were upper respiratory tract infection, diarrhea, fever, urinary tract infection, varicella, irritability and coughing. Full prescribing information is available at: http://www.spfiles.com/piclarinex.pdf.


        SOURCE: Schering-Plough Corporation



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send